CSIMarket Company Name, Ticker, Suppliers, else..
 
Immunome Inc   (NASDAQ: IMNM)
 
Price: $24.8550 $-0.11 -0.461%
Day's High: $25.729999542236328 Week Perf: -7.12 %
Day's Low: $ 24.75 30 Day Perf: -11.2 %
Volume (M): 179,884 52 Wk High: $ 30.06
Volume (M$): $ 0 52 Wk Avg: $20.87
Open: $25.39 52 Wk Low: $8.93



 Market Capitalization (Millions $) 2,815
 Shares Outstanding (Millions) 113
 Employees 177
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -254
 Cash Flow (TTM) (Millions $) 439
 Capital Exp. (TTM) (Millions $) 10

Business Description


Immunome Inc is a biotechnology company that specializes in the discovery and development of novel therapies for infectious diseases and cancer. The company uses its proprietary antibody discovery platform to identify and isolate antibodies from individuals who have developed strong immune responses against specific diseases. These antibodies can then be further developed into therapeutic treatments. Immunome focuses on creating targeted therapies that can be used to prevent or treat a wide range of infectious diseases, including COVID-19, as well as certain types of cancer. The company's goal is to harness the power of the immune system to develop innovative and effective treatments that can improve patient outcomes and address unmet medical needs.


   Company Address: 18702 N. Creek Parkway Bothell 98011 WA
   Company Phone Number: 939‑7410   Stock Exchange / Ticker: NASDAQ IMNM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -3.42%    
MRK   -5.04%    
PFE   -4.46%    
TEVA   -1.47%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Business Update

A Glimmer of Hope Immunome Inc. Unveils Promising Developments in the Battle Against Desmoid Tumors

Published Fri, Sep 13 2024 11:47 AM UTC

In this diligent age of scientific advancement, the realm of biotechnology finds itself afire with illuminating discoveries that promise to transform the landscape of oncological care. The latest missive from the esteemed domicile of Immunome, Inc. a paragon in the foray of developing innovative therapies, heralds a promising beacon for patients afflicted by desmoid tumors. ...
Business Update

Immunome, Inc. Pioneering the Future of Oncology with Promising Financial Results and Strategic Advancements

Published Tue, Aug 13 2024 1:07 AM UTC

: Immunome, Inc., a promising player in the biotechnology sector, has demonstrated resilience and innovation in its recent financial results for the second quarter of 2024. This article provides an overview of the company’s financial performance, strategic advancements in oncology therapies, and an outlook for future developments.In the dynamic and highly competitive land...
Business Update

Immunome Expands Antibody-Drug Conjugate Expertise Through Strategic Acquisitions

Published Thu, Jul 25 2024 1:47 PM UTC

In recent developments that demonstrate its commitment to advancing targeted cancer therapies, Immunome, Inc. (Nasdaq: IMNM), a renowned biotechnology firm based in Bothell, Washington, announced strategic moves that are poised to bolster its antibody-drug conjugate (ADC) capabilities. The company s latest initiative includes the closing of three influential transactions, ma...
Business Update

Immunome Amplifies Cancer Therapy Arsenal with Strategic Acquisition of Atreca’s Antibodies

Published Mon, May 20 2024 2:47 PM UTC

BOTHELL, Wash. Immunome, Inc. (Nasdaq: IMNM), a biotech firm renowned for its pioneering work in developing targeted cancer therapies, has announced the successful acquisition of antibodies and related assets from Atreca, Inc. This move is poised to significantly enhance Immunome’s therapeutic pipeline and fortify its position in the oncology sector. Strategic Acquisition...
Product Service News

Arrayjet's ArrayPlex Platform Empowers Immunome's Cancer Therapy Discovery

Published Mon, Mar 18 2024 9:44 AM UTC

In the pursuit of groundbreaking targeted cancer therapies, biotechnology company Immunome Inc. has chosen Arrayjet s ArrayPlex discovery platform to bolster its in-house high-throughput screening tools. Through this collaboration, Immunome aims to accelerate the discovery and development of first-in-class and best-in-class cancer therapies. Arrayjet, a leading provider of i...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 5.36
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.56
Working Capital Ratio 15.08
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.58 $
Revenues (TTM) -
Cash Flow (TTM) 3.87 $
Cash 4.59 $
Book Value 4.64 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,436,853
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.